You are here

RN624 For Pain Of Post-Herpetic Neuralgia

Last updated on November 17, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anniston, Alabama, 36207 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postherpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female of any race, at least 18 years of age.

- Patients must have pain present for more than 3 months after healing of the herpes
zoster skin rash.

- Has a pain score at screening that qualifies.

- Completes at least 3 average daily pain diaries during the 3 days prior to
randomization and has an average pain level that qualifies.

- Body Mass Index less than or equal to 39 kg/m2.

- If female, is post-menopausal, surgically sterile, or uses adequate contraception
consisting of 2 forms of birth control, one of which must be barrier method, is not
lactating, and is not breastfeeding.

- Male patients must agree that female spouses/partners will use contraception as
defined above or be of nonchildbearing potential (post-menopausal or surgically
sterile).

- Patients must be willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.

- Patients must consent in writing to participate in the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who cannot discontinue the use of other pain medications during the screening
period and during the study.

- Disqualifying scores on questionnaires.

- Other moderate to severe pain from other conditions.

- History of allergic or anaphylactic reaction to antibodies.

- Use of biologics, including any live vaccines within 3 months of the week prior to the
baseline visit.

- Unable to use acetaminophen.

- Disqualify laboratory values, Hepatitis B or C or HIV.

- Patients that have had a stroke or TIAs, dementia, epilepsy or seizures, or peripheral
neuropathy from other conditions.

- Significant cardiac disease within 3 months of the study such as angina, heart attack,
congestive heart failure, and other cardiac problems.

- Cancer other than basal cell or squamous cell carcinoma.

- Fails a urine test for illegal drugs including prescription drugs without a
prescription.

- Plans for surgery during the study.

- History of alcoholism or drug abuse in the past two years.

- Surgery for post-herpetic neuralgia.

- Any condition that the investigator feels would put the safety of the patient at risk.

NCT00568321
Pfizer
Completed
RN624 For Pain Of Post-Herpetic Neuralgia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE RN624 For Pain Of Post-Herpetic Neuralgia
Official Title  ICMJE A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Post-Herpetic Neuralgia
Brief SummaryThis study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Neuralgia, Postherpetic
Intervention  ICMJE
  • Drug: RN624
    50 mcg/kg
  • Drug: RN624
    200 mcg/kg
  • Drug: Placebo
    placebo
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: RN624
  • Active Comparator: 2
    Intervention: Drug: RN624
  • Placebo Comparator: 3
    Intervention: Drug: Placebo
Publications *Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, Verburg KM, Dyck PJ. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015 Jun;16(6):1163-76. doi: 10.1111/pme.12677. Epub 2015 Jan 16.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 13, 2009)
99
Original Estimated Enrollment  ICMJE
 (submitted: December 5, 2007)
129
Actual Study Completion Date  ICMJE January 2009
Actual Primary Completion DateDecember 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female of any race, at least 18 years of age.
  • Patients must have pain present for more than 3 months after healing of the herpes zoster skin rash.
  • Has a pain score at screening that qualifies.
  • Completes at least 3 average daily pain diaries during the 3 days prior to randomization and has an average pain level that qualifies.
  • Body Mass Index less than or equal to 39 kg/m2.
  • If female, is post-menopausal, surgically sterile, or uses adequate contraception consisting of 2 forms of birth control, one of which must be barrier method, is not lactating, and is not breastfeeding.
  • Male patients must agree that female spouses/partners will use contraception as defined above or be of nonchildbearing potential (post-menopausal or surgically sterile).
  • Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Patients must consent in writing to participate in the study.

Exclusion Criteria:

  • Patients who cannot discontinue the use of other pain medications during the screening period and during the study.
  • Disqualifying scores on questionnaires.
  • Other moderate to severe pain from other conditions.
  • History of allergic or anaphylactic reaction to antibodies.
  • Use of biologics, including any live vaccines within 3 months of the week prior to the baseline visit.
  • Unable to use acetaminophen.
  • Disqualify laboratory values, Hepatitis B or C or HIV.
  • Patients that have had a stroke or TIAs, dementia, epilepsy or seizures, or peripheral neuropathy from other conditions.
  • Significant cardiac disease within 3 months of the study such as angina, heart attack, congestive heart failure, and other cardiac problems.
  • Cancer other than basal cell or squamous cell carcinoma.
  • Fails a urine test for illegal drugs including prescription drugs without a prescription.
  • Plans for surgery during the study.
  • History of alcoholism or drug abuse in the past two years.
  • Surgery for post-herpetic neuralgia.
  • Any condition that the investigator feels would put the safety of the patient at risk.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00568321
Other Study ID Numbers  ICMJE A4091005
Has Data Monitoring CommitteeYes
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateOctober 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now